Silexion Therapeutics (SLXN) Cash from Investing Activities (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Cash from Investing Activities of -$7000.0 for Q4 2025, down 600.0% quarter-over-quarter from -$1000.0 in Q2 2025.
Silexion Therapeutics (SLXN) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$7000.0 for Q4 2025.
- In Q4 2025, Cash from Investing Activities changed N/A year-over-year to -$7000.0; the TTM figure through Mar 2026 stood at -$8000.0 (up 63.64% YoY), while the FY2025 annual figure was -$14000.0, up 36.36% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$7000.0, down from -$1000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $72000.0 in Q3 2023, with the low at -$16000.0 in Q3 2024.
- The 3-year median for Cash from Investing Activities is -$5000.0 (2023), against an average of $3750.0.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities plunged 122.22% in 2024, then changed 0.0% in 2025.
- Silexion Therapeutics' Cash from Investing Activities stood at -$4000.0 in 2023, then slumped by 300.0% to -$16000.0 in 2024, then jumped by 56.25% to -$7000.0 in 2025.
- Business Quant data shows SLXN's Cash from Investing Activities at -$7000.0 in Q4 2025, -$1000.0 in Q2 2025, and -$6000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Jun 30, 2026 | -1,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -6,000.00 |
| Mar 31, 2025 | -6,000.00 |
| Sep 30, 2024 | -16,000.00 |
| Sep 30, 2024 | -16,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Dec 31, 2023 | -4,000.00 |
| Dec 31, 2023 | -4,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -2,000.00 |